WEBULL

Undiscovered Gems in Global Markets to Watch in July 2026

Simply Wall St · 3d ago

As global markets navigate a landscape of cooling inflation, shifting rate hike expectations, and fluctuating energy prices, small-cap stocks have shown resilience amid broader market volatility. With economic indicators pointing to robust consumer spending and a steady labor market, investors are increasingly turning their attention to lesser-known companies that demonstrate strong fundamentals and growth potential in this dynamic environment.

Top 10 Undiscovered Gems With Strong Fundamentals Globally

Name Debt To Equity Revenue Growth Earnings Growth Health Rating
CNMC Goldmine Holdings 0.84% 32.52% 78.36% ★★★★★★
DeHua TB New Decoration MaterialLtd 0.63% 1.50% 2.14% ★★★★★★
Beijing Chunlizhengda Medical Instruments NA -2.67% -10.59% ★★★★★★
Base NA 11.66% 17.63% ★★★★★★
C-Rad NA 13.57% 13.83% ★★★★★★
GROUPE SFPI 18.02% 4.25% -29.76% ★★★★★★
Zhejiang Jolly PharmaceuticalLTD 21.31% 17.83% 29.70% ★★★★★☆
Sing Investments & Finance 0.15% 7.06% 8.65% ★★★★☆☆
Shengda ResourcesLtd 54.08% 7.99% 3.75% ★★★☆☆☆
Regina Miracle International (Holdings) 132.81% 0.48% -15.87% ★★★☆☆☆

Click here to see the full list of 160 stocks from our Global Undiscovered Gems With Strong Fundamentals screener.

We'll examine a selection from our screener results.

Global Standard Technology (KOSDAQ:A083450)

Simply Wall St Value Rating: ★★★★★★

Overview: Global Standard Technology, Limited operates in the environmental and energy sectors both in South Korea and internationally, with a market cap of approximately ₩777.82 billion.

Operations: Global Standard Technology's revenue streams are primarily derived from its activities in the environmental and energy sectors. The company's cost structure includes expenses related to these operations, impacting its financial performance. Notably, it has experienced fluctuations in net profit margin over recent reporting periods, reflecting changes in operational efficiency and market conditions.

Global Standard Technology, a smaller player in the semiconductor space, has seen its earnings grow by 24% over the past year, though this trails behind the industry's 27.4%. The company is trading at a significant discount of 27.8% below its estimated fair value, suggesting potential for upside. Over five years, it successfully reduced its debt to equity ratio from 5.7 to 3.2 and maintains more cash than total debt, indicating strong financial health. Despite recent volatility in share price and slower growth compared to peers, it boasts high-quality earnings and forecasts suggest an annual growth rate of around 20%.

KOSDAQ:A083450 Debt to Equity as at Jul 2026
KOSDAQ:A083450 Debt to Equity as at Jul 2026

WON TECHLtd (KOSDAQ:A336570)

Simply Wall St Value Rating: ★★★★★☆

Overview: WON TECH Co., Ltd. specializes in the production and sale of laser and energy-based equipment, serving both domestic and international markets, with a market cap of ₩449.69 billion.

Operations: WON TECH Co., Ltd. generates revenue primarily from its surgical and medical segment, amounting to ₩159.67 billion.

WON TECH Ltd., a South Korean company, is making waves with its recent financial maneuvers. The firm has been actively repurchasing shares, completing two buyback tranches this year alone, totaling 1.65% of outstanding shares for KRW 10,871 million. This move aims to stabilize its volatile stock price and enhance shareholder value. Additionally, WON TECH raised KRW 75 billion through a private placement of convertible bonds with zero coupon rate, set to mature in 2031. Despite negative earnings growth last year at -3.9%, the company’s forecasted annual earnings growth of nearly 14% suggests potential upside in the medical equipment sector.

KOSDAQ:A336570 Earnings and Revenue Growth as at Jul 2026
KOSDAQ:A336570 Earnings and Revenue Growth as at Jul 2026

Kuros Biosciences (SWX:KURN)

Simply Wall St Value Rating: ★★★★★★

Overview: Kuros Biosciences AG focuses on the commercialization and development of biologic technologies for musculoskeletal care across the USA, EU, and globally, with a market cap of CHF786.02 million.

Operations: Kuros Biosciences generates revenue primarily from its medical devices segment, which contributed $146.06 million.

Kuros Biosciences, a nimble player in the biotech field, recently turned profitable, making it challenging to compare its earnings growth with the broader industry. Trading at 78.6% below its estimated fair value suggests an attractive entry point for potential investors. The company stands out with no debt on its books and high-quality earnings, which adds a layer of financial stability. Despite not being free cash flow positive yet, Kuros is forecasted to grow earnings by 58% annually. Recent executive changes signal strategic shifts aimed at bolstering their presence in musculoskeletal applications and accelerating pipeline development.

SWX:KURN Debt to Equity as at Jul 2026
SWX:KURN Debt to Equity as at Jul 2026

Next Steps

Searching for a Fresh Perspective?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.